Previous 10 | Next 10 |
2023-11-17 07:35:11 ET More on BeiGene BeiGene: Staying On The Sidelines (Rating Downgrade) BeiGene regains full rights to cancer therapy from Novartis Seeking Alpha’s Quant Rating on BeiGene Historical earnings data for BeiGene Financial infor...
BRUKINSA is the first and only BTK inhibitor approved for follicular lymphoma in the European Union Approval was based on results from the ROSEWOOD trial in which BRUKINSA plus the anti-CD20 monoclonal antibody obinutuzumab achieved higher overall response rate compared to obinutuzumab al...
2023-11-14 16:26:26 ET Saudi Arabia's sovereign wealth fund cut its stake in parcel delivery giant FedEx ( NYSE: FDX ) and took a new position in Italian fashion firm Ermenegildo Zegna ( ZGN ) in Q3 2023, while raising its holdings in Pinduoduo-owner PDD ( NASDAQ: PDD ...
2023-11-09 17:35:34 ET More on BeiGene BeiGene: Staying On The Sidelines (Rating Downgrade) BeiGene regains full rights to cancer therapy from Novartis Jefferies starts BeiGene at buy, cites deep pipeline, Novartis partnership Seeking Alpha’s Quant Rat...
Generated total revenue of $781 million and global product sales of $595 million, a 102% and 70% increase from the prior-year period, respectively, while steadily improving operating leverage Global sales of BRUKINSA totaled $358 million, a 130% increase from the prior-year period, driven...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that the Company will participate in the Jefferies London Healthcare Conference on Wednesday, November 15 th , 2023 with a fireside chat at 2:00 pm GMT. A live webcast of this event can...
BeiGene Ltd. (BGNE) is expected to report $-3.16 for Q3 2023
2023-10-29 23:51:13 ET Summary Novartis recently completed the spin-off of Sandoz which improved its growth and margin profile. The biopharma business is in good shape with a decent collection of high-growth products and pipeline opportunities. The recent share price correctio...
2023-10-24 11:23:00 ET Summary Ambrx Biopharma Inc. common stock experienced an irrational selloff following the Phase 1/2 ESMO data release for its ADC candidate ARX517, presenting a buying opportunity. The company's technology for next-generation ADCs has shown safety benefits a...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...